Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13753
Abstract: We report on two Phase 1, open‐label, single‐arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epidermal growth factor… read more here.
Keywords: effect multiple; multiple dose; effect; osimertinib pharmacokinetics ... See more keywords
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Sign Up to like & getrecommendations! Published in 2022 at "Lung cancer"
DOI: 10.2139/ssrn.4043414
Abstract: INTRODUCTION Patients with life-threatening advanced non-small cell lung cancer (NSCLC) who harbor an exon 20 deletion and/or insertion mutation (EGFRex20 + ) have limited effective treatment options. The high dose 3rd generation tyrosine kinase inhibitor (TKI) osimertinib… read more here.
Keywords: patients advanced; phase multicenter; osimertinib patients; dose osimertinib ... See more keywords